載入...
New survival standards for advanced melanoma
The expectation for survival in patients with advanced melanoma now exceeds 50% at 5 years in patients treated with first-line combination ipilimumab and nivolumab, despite this regimen being associated with substantial toxicity. We discuss the latest updates from the Checkmate-067 study, framing th...
Na minha lista:
| 發表在: | Br J Cancer |
|---|---|
| Main Authors: | , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Nature Publishing Group UK
2020
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7188675/ https://ncbi.nlm.nih.gov/pubmed/32063602 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-020-0738-5 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|